CYP2C19 - Wikipedia
WEBCytochrome P450 2C19 (abbreviated CYP2C19) is an enzyme protein. It is a member of the CYP2C subfamily of the cytochrome P450 mixed-function oxidase system. This subfamily includes enzymes that catalyze metabolism of xenobiotics , including some proton pump inhibitors and antiepileptic drugs.
Pharmacogenetics of CYP2C19: functional and clinical implications of …
WEBMar 31, 2009 · Cytochrome P450 2C19 metabolizes many important drugs. In 2006, a variant allele (CYP2C19*17) associated with increased activity was discovered, but its likely clinical significance is controversial. Investigators disagree about the phenotype to be assigned to the two CYP2C19*17 genotypes. The aim of this study was to provide a …
Clopidogrel Therapy and CYP2C19 Genotype - Medical Genetics …
WEBMar 8, 2012 · USA.gov. Clopidogrel (brand name Plavix) is an antiplatelet medicine that reduces the risk of myocardial infarction (MI) and stroke in individuals with acute coronary syndrome (ACS), and in individuals with atherosclerotic vascular disease (indicated by a recent MI or stroke, or established peripheral arterial disease) (1).
CYP2C19 gene: MedlinePlus Genetics
WEBEnzymes produced from cytochrome P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. The CYP2C19 gene provides instructions for making an enzyme that is found primarily in liver cells in a cell structure called the endoplasmic reticulum, which is involved in protein processing and ...
PharmVar GeneFocus: CYP2C19 - PMC - National Center for …
WEBThe CYP2C19 gene was first characterized in 1991 ( 4 ), and is one of four CYP2C subfamily genes, located on chromosome 10q23.33 ( CYP2C8, CYP2C9, CYP2C18 and CYP2C19) ( 5 ). The first CYP2C19 variant allele, implicated in poor metabolism ( CYP2C19*2 ), was reported in 1994 ( 6 ).
CYP2C19 - an overview | ScienceDirect Topics
WEBCYP2C19. CYP2C19 catalyzes the metabolism of more than 12 clinically important drugs, such as omeprazole (antiulcerative), (S)-mephenytoin (anticonvulsant), and diazepam (anxiolytic), etc. (Lee, 2012 ). It plays an important role in the proton pump–inhibitor therapy for peptic ulcer and gastroesophageal reflux diseases.
Global distribution of CYP2C19 risk phenotypes affecting
WEBOct 20, 2020 · To determine the predictive prevalence of high-risk phenotypes due to CYP2C19 genetic variants collectively in the world population and to establish a correlation how the identified high-risk ...
Genetic polymorphism of CYP2C19 and subcortical variability …
WEBSep 8, 2021 · CYP2C19, which is expressed in the human fetal brain during neurodevelopment, shows affinity for endogenous compounds including monoaminergic neurotransmitters, steroid hormones, and...
Frequencies of clinically important CYP2C19 and CYP2D6 …
WEBJul 29, 2019 · CYP2C19 and CYP2D6 are important drug-metabolizing enzymes that are involved in the metabolism of around 30% of all medications.
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet …
WEBFeb 14, 2019 · Although clopidogrel is the most commonly prescribed P2Y 12 inhibitor, it is associated with an increased risk of major adverse cardiovascular events in patients carrying loss-of-function CYP2C19 alleles. In contrast, CYP2C19 genotype does not impact clinical response to prasugrel or ticagrelor.
Skip to content